Star Combo surges on Bio-E acquisition
Leading distributor and manufacturer of branded premium health and natural beauty products, Star Combo Pharma Ltd (ASX:S66) has made a transformational acquisition which will not only contribute underlying earnings of $14.7 million in fiscal 2019, but will also provide the group with strategic and competitive advantages across its core markets.
The new addition to Star Combo is Bio-E, a provider of innovative natural and health focused products to consumers.
The upfront consideration of $60 million represents a conservative EBITDA multiple of 4.1 relative to the group’s forecast fiscal 2019 earnings.
The raising comprises a placement of $50 million to professional and sophisticated investors at 55 cents per share and a share purchase plan of up to $1 million at 56 cents per share.
The vendors also received 30 million shares in Star Combo at 60 cents per share, equating to $18 million.
From a strategic perspective, the acquisition of Bio-E is consistent with Star Combo's strategy to grow its branded sales and product development capability, and provides an opportunity to combine the strong (TGA licensed) manufacturing and product development capability of Star Combo and the marketing and distribution expertise of Bio-E.
The acquisition of Bio-E provides Star Combo with the capability to quickly develop, commercialise, market and sell new products.
Five new products in pipeline in 2020
Star Combo and Bio-E have already collaborated to develop and commercialise ‘Sleep Diet’, a new pill aimed at improving sleep and weight loss, with forward orders of over $10 million since its launch in May 2019.
Highlighting the significance of the acquisition, Star Combo Chairman Richard Allely said, “This is a transformational acquisition for Star Combo and accelerates our transition from a contract manufacturing business to a fast growth, high margin, branded business.
“We first met Bio-E when we developed and formulated the new Sleep Diet product for them.
“Both companies quickly recognised the significant synergies by combining our business and bringing our complementary skill sets together.
“We are excited about the significant growth opportunities that both businesses have going into FY20.
“Star Combo’s Living Healthy brand is gaining traction in Australia and is now on shelves in China.
“Likewise, Bio-E new product Sleep Diet has generated over $10 million in new orders since its launch in May this year and we are expecting to launch up to 5 new products in FY20”.
Strong earnings growth and robust margins
As an Australian owned company established in Melbourne, Bio-E has grown quickly in recent years, with fiscal 2019 revenue and EBITDA forecasts implying growth of 180% and 240% per annum respectively since 2017.
It is important to note Star Combo’s already strong position in product innovation, manufacturing and distribution, as this will enable the combined group to quickly gain traction from its expanded product base.
The group’s efficiencies across its vertically integrated model are evidenced by the comparatively high gross margins of 80%.
Based in Sydney, Star Combo’s products are distributed to both Australian and overseas markets.
Star Combo has offices and distribution agreements in China and currently supplies Australian pharmacy lines as well as distributing to over 450 Terry White and Symbion chemists and wholesale customers in Australia and China.
The distribution side of the company’s business was enhanced substantially in February when the company acquired the businesses of Koala Mall Pty Ltd and Austoyou Group Pty Ltd for A$10 million.
This was a game changing development for the group, particularly in terms of opening up direct selling channels to Chinese consumers.
The significance of this acquisition was reflected in the company’s share price reaction as it immediately surged from 55 cents per share to 85 cents per share.
New earnings metrics imply 100% share price upside
This Bio-E acquisition transforms Star Combo’s growth profile, and in doing so could potentially trigger a significant share price re-rating as a more aggressive PE multiple is attributed to the stock.
The likelihood of a share price re-rating is highlighted below in the comparisons of peers on an enterprise value to EBITDA basis.
Aside from the $1 billion Tassal Group (ASX:TGR), Star Combo’s EV/EBITDA ratio is the only single digit multiple.
Further, it is at a discount of more than 50% to the median sector average of 15.7.
Some of the comparable businesses are unprofitable, and there are few that generate the high gross margins of 80% that we previously referred to.
The implied enterprise value in the above table is based on the capital raising price of 55 cents per share.
Consequently, if Star Combo were priced in line with the median multiple of its peers, this would imply a share price of approximately $1.15.
Bearing this in mind, even though shares in Star Combo have increased more than 30% to a high of 92.5 cents in morning trading, the implied EV/EBITDA share price represents further upside of 25%.
As investors come to acknowledge the above growth trajectory and the prospect for sustaining strong earnings momentum, as should be indicated when management provides guidance in August, it could well be the case that Star Combo’s enterprise value will be more in accord with the group’s earnings expectations for fiscal 2020.
Other share price catalysts in fiscal 2020 include the proposed launch of up to 5 new products, as well as product registrations that are currently in the pipeline.
The key takeaways
The Bio-E acquisition is a company maker from many perspectives, but there are a few aspects that are worth highlighting.
Firstly, this is a highly earnings accretive addition to Star Combo’s business, effectively transitioning it to a business with robust profitability at an early stage.
The company is debt free with substantial infrastructure in place to ramp up production in response particularly to the fast growing Chinese health and well-being market.
Consequently, Star Combo has the ability to generate significantly higher revenues from increased production off a relatively fixed cost base, resulting in a substantial proportion of income dropping straight to the bottom line.
The group is a highly efficient, vertically integrated business that benefits from complete supply chain management.
This is extremely important in terms of the company continuing to benefit from healthy margins as it isn’t reliant on intermediaries at any stage between product manufacture and consumer purchase.
Not only does this provide optimum cost management, strong margins and competitive strengths, but it also assists the group in operating efficiently and providing its end markets with reliability of supply.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.